INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $10,935,000 | -18.9% | 13,500,000 | -25.0% | 0.38% | -41.9% |
| Q2 2020 | $13,479,000 | -8.5% | 18,000,000 | 0.0% | 0.65% | -37.6% |
| Q1 2020 | $14,732,000 | -9.1% | 18,000,000 | +12.5% | 1.04% | +76.0% |
| Q4 2019 | $16,205,000 | +17.6% | 16,000,000 | 0.0% | 0.59% | +31.3% |
| Q3 2019 | $13,775,000 | -4.5% | 16,000,000 | 0.0% | 0.45% | +6.1% |
| Q2 2019 | $14,420,000 | +21.2% | 16,000,000 | +33.3% | 0.42% | -33.6% |
| Q1 2019 | $11,895,000 | -11.9% | 12,000,000 | -18.0% | 0.64% | +7.4% |
| Q4 2018 | $13,509,000 | -8.5% | 14,636,000 | 0.0% | 0.60% | +93.8% |
| Q3 2018 | $14,768,000 | +23.6% | 14,636,000 | +7.3% | 0.31% | -31.0% |
| Q2 2018 | $11,946,000 | -42.6% | 13,636,000 | -47.4% | 0.44% | -20.0% |
| Q1 2018 | $20,796,000 | +101.0% | 25,912,000 | +100.0% | 0.56% | +105.9% |
| Q4 2017 | $10,348,000 | – | 12,956,000 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Silver Point Capital L.P. | 57,420,000 | $44,527,000 | 5.17% |
| Birch Grove Capital LP | 10,003,000 | $7,934,000 | 4.14% |
| PenderFund Capital Management Ltd. | 9,605,000 | $9,491,000 | 2.41% |
| Context Capital Management, LLC | 9,887,000 | $7,671,000 | 1.05% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $45,738,000 | 0.90% |
| DeepCurrents Investment Group LLC | 35,892,000 | $27,953,000 | 0.74% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 22,977,000 | $18,267,000 | 0.70% |
| WHITEBOX ADVISORS LLC | 23,150,000 | $17,847,000 | 0.56% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 27,397,000 | $21,720,000 | 0.46% |
| OAKTREE CAPITAL MANAGEMENT LP | 19,435,000 | $15,079,000 | 0.26% |